Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

This study has been terminated.
(Study protocol amended to a new treatment regimen: study DAVFU-006.)
Sponsor:
Information provided by (Responsible Party):
Galectin Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT00110721
First received: May 12, 2005
Last updated: March 5, 2012
Last verified: March 2012
  Purpose

This is a Phase II, multi-center study of GM-CT-01 which has been shown to increase the anti-tumor activity of 5-fluorouracil (5-FU) in mice. 5-FU is a chemotherapy drug commonly used in cancer patients. In this Phase II study, patients with colon cancer which has spread, despite treatment with approved therapies, will receive GM-CT-01 plus 5-FU in monthly cycles for at least 2 cycles or until their disease progresses.


Condition Intervention Phase
Colorectal Cancer
Drug: GM-CT-01 plus 5-Fluorouracil
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Multi-Center, Open-Label Trial to Evaluate the Efficacy and Safety of Intravenous GM-CT-01 in Combination With 5-Fluorouracil When Administered in Monthly Cycles as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Galectin Therapeutics Inc.:

Primary Outcome Measures:
  • frequency of objective complete or partial tumor response [ Time Frame: 20 patients completed treatment ] [ Designated as safety issue: No ]
    Tumor response as characterized by Response Evaluation Criteria in Solid Tumors (RECIST) criteria

  • frequency of stable disease [ Time Frame: 20 patients completed treatment ] [ Designated as safety issue: No ]
    Stable disease as measured by CT imaging or carcinoembryonic antigen (CEA) levels


Secondary Outcome Measures:
  • safety of GM-CT-01 plus 5-FU [ Time Frame: 20 patients completed treatment ] [ Designated as safety issue: Yes ]
    Frequency and type of AE/SAE and ancillary clinical indicators including Eastern Cooperative Oncology Group (ECOG) performance and quality of life.


Enrollment: 20
Study Start Date: May 2005
Study Completion Date: February 2008
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: GM-CT-01 plus 5-Fluorouracil
    Single use vials, combined regimen of GM-CT-01 / 5-Fluorouracil (280 mg/m2 /500 mg/m2) given for 4 consecutive days in a 28 day cycle until disease progression.
    Other Name: DAVANAT
Detailed Description:

A Phase I study of 40 patients showed that GM-CT-01 in different doses plus 5-FU was well tolerated in patients with different types of solid tumors who failed standard, approved treatments. The main reason for doing this Phase II study in advanced colorectal cancer patients is to verify the safety observations in the early Phase I study and further evaluate the efficacy of these drugs' combination to stabilize tumors, preventing further growth and potentially shrink tumors.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Has a histologically-proven adenocarcinoma of the colon or rectum
  • Has documentation of locally advanced or metastatic colorectal cancer not amenable to curative surgery or radiotherapy
  • Eligible subjects are those whose unresectable, locally advanced and/or metastatic colorectal cancer has progressed during or after receiving treatment with at least two, but not more than three, lines of therapy that collectively must have included at a minimum all of the following agents: 5-fluorouracil or capecitabine, irinotecan, and oxaliplatin (unless, in the opinion of the investigator, the subject is not able to receive irinotecan and/or oxaliplatin due to medical contraindications, in which case irinotecan and/or oxaliplatin are not required to have been included in the prior lines of therapy). Adjuvant chemotherapy following definitive management of the primary lesion in the colon or rectum is allowed and will not be counted as a line of therapy.
  • Has 1 or more measurable lesion(s) ("target lesion[s]") according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria.

The same diagnostic imaging method must be used throughout the study to evaluate the lesions; and clinically detected lesions will only be considered measurable when they are superficial (e.g., skin nodules and palpable lymph nodes).

  • Has an ECOG performance status of 0-2
  • Has a life expectancy greater than 3 months
  • Has the ability to understand the nature of the study and any hazards of participating in it; to communicate satisfactorily with the Investigator; and to participate in, and comply with, the requirements of the entire study
  • A female of childbearing potential must have a negative serum screening test for pregnancy and agree to practice abstinence or use an effective method of contraception
  • Has had all aspects of the protocol explained and written informed consent obtained

Exclusion Criteria:

  • Has central nervous system metastasis
  • Has bony metastasis as the sole metastasis
  • Has other concomitant or previous malignancy in the past 3 years, except:

    • adequately treated in situ carcinoma of the uterine cervix;
    • basal or squamous cell carcinoma of the skin; and/or
    • melanoma in situ.
  • Is receiving concomitant anti-neoplastic treatment; has received radiation therapy in the past 3 weeks; has been treated with anti-angiogenesis agents, including bevacizumab, in the past 4 weeks; or has been treated with any other chemotherapeutic agents in the past 4 weeks (6 weeks for mitomycin C and nitrosoureas).
  • Has an active infection
  • Has congestive heart failure (Class III or IV in the New York Heart Association functional classification system)
  • Has a hemoglobin level of < 8.5 gm/dL
  • Has a platelet count of < 100,000/mm3
  • Has a neutrophil count of < 1,500/mm3
  • Has a serum creatinine level of > 2.0 mg/dL
  • Has liver aminotransferase and alkaline phosphatase levels that are > 2.5 times the laboratory's upper limit of normal (ULN) in a subject with no liver metastases, and levels that are > 5 times the laboratory's ULN in a subject with liver metastases
  • Has a total bilirubin level that is > 2 times the laboratory's ULN
  • Has pulmonary DLCO < 60% of predicted
  • Has known or clinically suspected infection with human immunodeficiency virus (HIV)
  • Has participated within 30 days, or will participate concurrently, in another investigational drug or vaccine study
  • Has a history of drug or alcohol dependence in the past 3 years
  • Has other serious, non-malignant, significant, acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study
  • Has known intolerance to 5- FU
  • Has previously participated in a GM-CT-01 clinical trial
  • Has known hypersensitivity to GM-CT-01 or any of its components
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00110721

Locations
United States, Connecticut
Medical Oncology and Hematology
Waterbury, Connecticut, United States, 06708
United States, Florida
Hematology-Oncology Associates of the Treasure Coast
Port St. Lucie, Florida, United States, 34952
United States, Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana, United States, 70121
United States, Michigan
University of Michigan Comprehensive Cancer Center
Ann Arbor,, Michigan, United States
Israel
Soroka University Medical Center
Beer-Sheva, Israel, 84101
Shaare Zedek Medical Center, Oncology
Jerusalem, Israel, 91031
Sponsors and Collaborators
Galectin Therapeutics Inc.
  More Information

Additional Information:
No publications provided

Responsible Party: Galectin Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT00110721     History of Changes
Other Study ID Numbers: DAVFU-003
Study First Received: May 12, 2005
Last Updated: March 5, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Galectin Therapeutics Inc.:
colorectal cancer
DAVANAT
5-fluorouracil

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Fluorouracil
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014